Literature DB >> 1568181

Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia with cyclosporin A.

T Murayama1, S Imoto, T Takahashi, M Ito, S Matozaki, T Nakagawa.   

Abstract

Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) is a lymphoma-like disease. Although the histologic appearance of this disease is benign, it is clinically malignant, with chemotherapy being ineffective and the prognosis being poor. In this article, the authors report the results of treating two patients with AILD with cyclosporin A. One patient had cervical lymphadenopathy and fever, and AILD was refractory to both chemotherapy and alpha-interferon. However, treatment with cyclosporin A achieved complete remission. The other patient had generalized lymphadenopathy, and cyclosporin A was used as the treatment of first choice. Complete remission also was achieved in this patient, who still is in remission. These two cases demonstrate that cyclosporin A can be effective for treating AILD.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1568181     DOI: 10.1002/1097-0142(19920515)69:10<2567::aid-cncr2820691029>3.0.co;2-m

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

Review 1.  Peripheral T-cell lymphoma.

Authors:  Wing Y Au; Raymond Liang
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

Review 2.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

3.  Polyarthritis, rash and lymphadenopathy: case reports of two patients with angioimmunoblastic lymphadenopathy presenting to a rheumatology clinic.

Authors:  M A Layton; C Musgrove; P T Dawes
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

4.  Cyclosporine, prednisone, and high-dose immunoglobulin treatment of angioimmunoblastic T-cell lymphoma refractory to prior CHOP or CHOP-like regimen.

Authors:  Xing-Gui Chen; He Huang; Ying Tian; Cheng-Cheng Guo; Chao-Yong Liang; Yao-Ling Gong; Ben-Yan Zou; Rui-Qing Cai; Tong-Yu Lin
Journal:  Chin J Cancer       Date:  2011-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.